Carl Zeiss Meditec’s re-rating journey should continue further
21/02/24 -"Despite our near-term estimates being slightly moderated due to the destocking of consumables and anticipated impact from volume-based procurement headwinds, our target price resets higher by c.4%, ..."
Pages
59
Language
English
Published on
21/02/24
You may also be interested by these reports :
07/01/26
Yesterday, Meta announced a delay in the international rollout of the Ray-Ban display smart glasses. The market reacted positively to this news, on ...
30/12/25
Despite revising our estimates and target price downward, DiaSorin remains a compelling investment opportunity. This is underpinned by strong ...
15/12/25
We have revised our estimates upwards to account for enhanced profitability, despite the effects of tariffs and foreign exchange headwinds. This ...
11/12/25
CZM reported its full-year FY2024-25 results, aligning with guidance. Sales growth was supported by contributions from both segments, though ...